← Back to Dashboard

AUROPHARMA Aurobindo Pharma Ltd. — Smart-Money Activity, F&O Buildup & Bulk Deals

Sector: Healthcare
₹ 1,451.80
-0.72%

Smart Money Verdict synthesis of derivatives, deals, and promoter files

No significant institutional activity detected
Derivative metrics and institutional flows are quiet. No recent bulk deals or insider disclosures have been reported.

Analysis what the data is telling us about AUROPHARMA

In the last completed session, Aurobindo Pharma Ltd. closed -0.80% with futures open interest moving -0.2%. Positioning is neutral — neither side is decisively adding or unwinding right now. The stock's option PCR sits at 0.60, indicating heavy call-side writing — option dealers see resistance overhead. Max-pain strike at ₹1,480 sits 1.9% above the current price, a mild magnet near expiry.

There have been no notable bulk or block deals from FIIs, mutual funds, or insurance companies in Aurobindo Pharma Ltd. over the last 30 sessions.

Putting it together, the smart-money picture for Aurobindo Pharma Ltd. is balanced between accumulation and distribution forces.

F&O Positioning EOD derivatives setup

Buildup Class
Neutral
bias: neutral
Futures OI
17,153,950
-37950 (-0.2%)
Option PCR (OI)
0.60
heavy call writing
Max Pain Strike
₹ 1,480
writer loss minimized strike

Quote Details key metrics & weights

Previous Close
₹ 1,462.30
yesterday's EOD close
Index Contribution
not a Nifty 50 constituent
Traded Volume
506,600
live shares traded today
Upcoming Earnings
no report scheduled

Technical Snapshot from 400 sessions of price history

RSI (14)
51.2
neutral momentum
52-Week High
₹ 1,550.00
-6.3% from high
52-Week Low
₹ 1,016.10
+42.9% above low
200-DMA
₹ 1,224.77
+18.5% · above trend
50-DMA
₹ 1,420.29
+2.2% from 50-DMA
1-Year Return
+27.7%
1M -2.4%

Key Fundamentals headline ratios · Healthcare

P/E (TTM)
24.0
price / earnings
P/B
2.2
price / book
ROE
9.9%
return on equity
Market Cap
₹ 83,533 Cr
total market value
Dividend Yield
0.27%
trailing yield
EPS (TTM)
₹ 60.39
earnings per share

Fundamental ratios sourced from public market data, refreshed periodically; verify against company filings before relying on them.

Institutional Deals last 30 sessions (bulk & block)

No institutional bulk or block deals recorded for this stock in the last 30 sessions.

Insider & Promoter Filings last 60 days

No insider disclosures filed for this stock in the last 60 days.

Option Chain Ladder nearest expiry 2026-06-30 · spot 1,452 · EOD 2026-06-08

Option writers expect range between 1,400 and 1,600+10.2% upside, -3.6% downside.
upside-skewed
Call OI (writers) Strike Put OI (writers)
550
IV 78% Δ 0.70 θ -2.3 ν 1
1340
34,100 +2k
0
1360
88,000 +3k
IV 27% Δ -0.14 θ -0.5 ν 1
3,300
IV 40% Δ 0.73 θ -1.3 ν 1
1380
151,250 +3k
IV 26% Δ -0.19 θ -0.5 ν 1
101,750 +0k
IV 30% Δ 0.72 θ -1.0 ν 1
1400 S
430,650 +11k
IV 25% Δ -0.25 θ -0.6 ν 1
58,300 +0k
IV 31% Δ 0.65 θ -1.1 ν 1
1420
117,700 -5k
IV 26% Δ -0.33 θ -0.7 ν 1
99,000
IV 26% Δ 0.59 θ -1.0 ν 1
1440
160,050 -11k
IV 25% Δ -0.41 θ -0.7 ν 1
347,600 +21k
IV 27% Δ 0.50 θ -1.0 ν 1
1460
427,900 +11k
IV 25% Δ -0.50 θ -0.7 ν 1
385,550 +110k
IV 27% Δ 0.42 θ -1.0 ν 1
1480 MP
320,100 -55k
IV 25% Δ -0.59 θ -0.6 ν 1
781,550 +24k
IV 27% Δ 0.35 θ -0.9 ν 1
1500
218,900 -3k
IV 24% Δ -0.68 θ -0.5 ν 1
85,800
IV 27% Δ 0.27 θ -0.8 ν 1
1520
56,650
IV 29% Δ -0.71 θ -0.6 ν 1
108,350 -11k
IV 28% Δ 0.22 θ -0.7 ν 1
1540
12,650
144,100 -5k
IV 28% Δ 0.17 θ -0.6 ν 1
1560
19,250
122,650 -1k
IV 29% Δ 0.14 θ -0.6 ν 1
1580
0
IV 67% Δ -0.66 θ -1.8 ν 1

Chain Interpretation

Spot Underlying 1,451.80
Key Resistance (R) 1,600
Key Support (S) 1,400
Max Pain Strike (MP) 1,480
Concentrations of Option open interest show strong barrier levels. Option writers defend these levels, especially heading into monthly derivatives expiry.

Strategy Builder multi-leg payoff for AUROPHARMA options · 2026-06-30 expiry

Underlying: AUROPHARMA · Spot: ₹ 1,451.80 · Expiry: 2026-06-30 · Lot: 550

Legs

Side
Type
Strike
Qty
Premium
Net premium
Max profit
Max loss
Breakevens
Position Delta
Position Theta/day
Position Vega/1% IV

Payoff at expiry

Latest News recent coverage from Reuters, Simply Wall St, MT Newswires and others